Plain-English translation of NCT07619638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a microbiome-targeted food supplement designed to help restore healthy bacteria in your gut and reduce inflammation from ulcerative colitis. The medication works by promoting the growth of beneficial bacteria that produce short-chain fatty acids, which help calm intestinal inflammation. This treatment offers a non-immunosuppressive option for people whose symptoms persist despite standard therapy.
Many people with ulcerative colitis continue to have symptoms and inflammation even when taking standard medications like mesalamine, and some want to avoid stronger immunosuppressive drugs. Research shows that people with active ulcerative colitis have unhealthy gut bacteria with fewer beneficial species, so this medication aims to restore that balance and reduce inflammation naturally.
You likely qualify if…
You likely don't qualify if…
You will take the medication or a matching placebo by mouth once daily for 24 weeks, continuing any stable mesalamine therapy you're already on. You'll attend study visits, provide stool samples at baseline and at weeks 12 and 24, undergo a flexible sigmoidoscopy at week 24 to check your colon's healing, and complete symptom diaries and questionnaires. If your symptoms worsen at any time, you can receive additional treatment without leaving the trial.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Turkey (Türkiye)